Most researchers trying to source CJC-1295 in Tillo soon discover that local retail options are virtually absent. This matters because CJC-1295 quality varies dramatically across the market — from pharmaceutical-grade 99%+ purity to products with serious contamination — and the vendor controls every quality variable. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. Use this guide to verify vendor quality systematically — the standards covered in this guide are universal across all research contexts.
What Studies Say About CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Tillo studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Evaluate CJC-1295 Vendors
The first step for any Tillo researcher sourcing CJC-1295 is finding vendors with verified community track records — commercial rankings reflect SEO budgets rather than product quality. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone cannot verify molecular identity. The combination of community reputation data and your own COA analysis is the most reliable sourcing approach — community feedback surfaces recurring issues no single purchase reveals, and vice versa. For Tillo researchers making a first CJC-1295 purchase: work through this evaluation framework first, begin with a small order, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Tillo
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and limited human studies. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution stored refrigerated at 2-8°C and used within 30 days; reconstitute only with bac water. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at trace quantities, and no discount compensates for this missing data. PubMed and bioRxiv provide the most complete literature coverage for CJC-1295 research; prioritise peer-reviewed studies with characterised source material over unreviewed preprints or forum reports.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
